| Drug Name |
Telotristat ethyl |
| Drug ID |
BADD_D02503 |
| Description |
Telotristat only approved oral therapy for carcinoid syndrome diarrhea. Telotristat was approved by the FDA in March, 2017 as Xermelo. |
| Indications and Usage |
As a serotonin synthesis inhibitor, telotristat etiprate, has the potential to reduce serotonin levels and address the key elements of carcinoid syndrome. |
| Marketing Status |
approved; investigational |
| ATC Code |
Not Available |
| DrugBank ID |
DB12095
|
| KEGG ID |
D09974
|
| MeSH ID |
C000621725
|
| PubChem ID |
25181577
|
| TTD Drug ID |
D0RE6T
|
| NDC Product Code |
70183-125; 11014-0462; 70720-125 |
| UNII |
8G388563M7
|
| Synonyms |
telotristat ethyl | Xermelo | LX1032 |
